AstraZeneca

Heptares, AstraZeneca ink cancer immuno-oncology deal

Thursday, August 6, 2015

Heptares Therapeutics, a U.K.-based clinical-stage company, and AstraZeneca have entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialize the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds. AstraZeneca will focus on exploring HTL-1071 and any additional compounds across a range of cancers, including in combination with its existing portfolio of immunotherapies.

[Read More]

Eolas Therapeutics, AstraZeneca partner

Wednesday, July 1, 2015

Eolas Therapeutics, a therapeutic development company based in Carlsbad, Calif., has entered into a worldwide license and partnership agreement with AstraZeneca on the Eolas Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other indications. The EORA program was awarded a Blueprint Neurotherapeutics (BPN) grant from the NIH for the development of the program from the preclinical stage through phase I clinical trials.

[Read More]

Syndax appoints Dr. Briggs Morrison CEO, Michael Metzger president and COO

Monday, June 15, 2015

Syndax Pharmaceuticals, a privately held oncology company based in Waltham, Mass., has announced that Briggs W. Morrison, M.D., is joining the company as CEO and a member of the board of directors, and Michael A. Metzger is joining the company as president and chief operating officer. Morrison joins Syndax from AstraZeneca, where he was executive vice president, global medicines development and chief medical officer. Metzger joins from Regado Biosciences, where he was president and CEO through the company’s strategic merger with Tobira Therapeutics.

[Read More]

AstraZeneca partners with two Algerian companies

Monday, June 8, 2015

AstraZeneca has partnered with two Algerian companies, AHT Health SARL of SALHI group and Hasnaoui Finance SARL Group. The companies have created the joint venture AstraZeneca Al Djazair to build a new production unit in Algeria. This commitment, which will generate investments and skilled jobs, is part of the Algerian government’a strategy to modernize and develop the pharmaceutical sector of the country. The new facility would formulate AstraZeneca medicines in cardiovascular diseases, gastroenterology, oncology and diabetes for the Algerian healthcare community.

[Read More]

AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden

Wednesday, May 20, 2015

AstraZeneca plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics. The new facility will supply medicines for clinical trial programs of AZ and MedImmune, the company’s global biologics R&D arm, from the end of 2018, and will deliver finished products for commercial use once fully operational by 2019.

[Read More]